<DOC>
	<DOCNO>NCT01761461</DOCNO>
	<brief_summary>The optimal regimen adjuvant treatment establish GC yet . We plan compare TS-1 , TS-1/oxaliplatin without RT D2 resect gastric cancer .</brief_summary>
	<brief_title>Phase III Randomized Trial Adjuvant Chemotherapy With S-1 v S-1/Oxaliplatin ± Radiotherapy Completely Resected Gastric Adenocarcinoma : The ARTIST II Trial</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>1 . Histologically proven gastric gastroesophageal adenocarcinoma 2 . ≥ D2 lymph node dissection , curative gastrectomy 3 . Stage II , III ( AJCC 2010 ) N ( stage N0 exclude ) 4 . Age &gt; 19 5 . ECOG 02 6 . No distant metastasis 7 . Adequate bone marrow function ( ANC ≥ 1,500/ul , blood platelet ≥ 100,000/ul , haemoglobin ≥ 10g/dl , transfusion allow ) 8 . Adequate renal function ( serum creatinine ≤ 1.5mg/dl ) 9. liver function ( serum bilirubin ≤ 1.5mg/dl , AST/ALT ≤ 3 time ( normal value ) 10 . Written inform consent 11 . Possible oral intake ( food , drug ) Subjects present follow include study 1 . Active infection require antibiotic 2 . Pregnant , lactate woman 3 . Concurrent systemic illness appropriate chemotherapy 4 . Resection margin ( + ) permanent pathology 5 . Pathologic stage I IV ( Ia Ib accord AJCC 2010 ) 6 . Inadequate surgery include D0 , D1 resection , dissect LNs le 12 7 . Paraaortic lymph node ( + ) , pathologically proven 8. woman potential childbearing employ adequate contraception</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>